4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

Nicole DeFeudis

Editor

4D Molecular Therapeutics announced Wednesday that its inhalable gene therapy for cystic fibrosis showed signs of improved quality of life in an early look from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

Nicole DeFeudis

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Dutch biotech gets $146M for late-stage trials in three metabolic disorders

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

UnitedHealth Group CEO Andrew Witty steps down

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

Editor

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients